1 For overall survival (OS), the combination of nivolumab plus ipilimumab showed a significant improvement in median OS compared with lenvatinib (Lenvima) or sorafenib (Nexavar) at 23.7 vs 20.6 months ...

Teva Pharmaceuticals International GmbH, a subsidiary of Teva, has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of ...

The FDA approval is based on the results of the open-label KEYNOTE-224 trial, which enrolled 104 patients who had relapsed after or were refractory to Bayer’s Nexavar (sorafenib), the first-line ...